Newron Pharmaceuticals S.p.A. (NWPHF) Discusses FDA Clinical Hold and Safety Concerns in ENIGMA-TRS Program for Treatment-Resistant Schizophrenia Transcript

Newron Pharmaceuticals S.p.A. (NWPHF) Discusses FDA Clinical Hold and Safety Concerns in ENIGMA-TRS Program for Treatment-Resistant Schizophrenia Octo…

Continue in Briflio to read, react, comment, and share.